SCHEMBL13625152

SCHEMBL13625152

CC(O)c1cccn2cc(-c3ccc(CC(CCO)NC(=O)OC(C)(C)C)cc3)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CENPE Q02224 2/20 0.50
ATM Q13315 1/20 0.41
ALDH1A1 P00352 3/20 0.38
ALDH1A2 O94788 1/20 0.38
ALDH1A3 P47895 1/20 0.38
KDM4E B2RXH2 3/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
APP P05067 3/20 0.36
PTPRB P23467 2/20 0.35
DHODH Q02127 1/20 0.35
ITGA4 P13612 2/20 0.35
ITGB7 P26010 2/20 0.35
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GNRHR P30968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2617327 1.00 CENPE (0.50) CENPEATMALDH1A1ALDH1A2ALDH1A3
SCHEMBL2617329 0.91 CENPE (0.49) CENPEATMALDH1A1ALDH1A2ALDH1A3
SCHEMBL13456915 0.87 CENPE (0.49) CENPEALDH1A1ALDH1A2ALDH1A3KDM4E
SCHEMBL13162714 0.86 CENPE (0.45) CENPEATMALDH1A1ALDH1A2ALDH1A3
SCHEMBL13644421 0.81 CENPE (0.42) CENPEATMALDH1A1ALDH1A2ALDH1A3
SCHEMBL2617337 0.80 CENPE (0.51) CENPEATMALDH1A1KDM4EKMT2A
SCHEMBL3463331 0.80 CENPE (0.51) CENPEATMALDH1A1ALDH1A2ALDH1A3
SCHEMBL2105673 0.80 CENPE (0.51) CENPEATMALDH1A1KDM4EKMT2A
SCHEMBL14870853 0.80 CENPE (0.44) CENPEALDH1A1ALDH1A2ALDH1A3KDM4E
SCHEMBL13183963 0.80 CENPE (0.44) CENPEALDH1A1ALDH1A2ALDH1A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772507-B2 Imidazole-benzamide anti-cancer agents CYTOKINETICS, INC. (US) 2014-07-08 US disclosed
US-20130096315-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS QIAN XIANGPING (US) 2013-04-18 US disclosed
US-7618981-B2 to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide CYTOKINETICS, INC. (US) 2009-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096315-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS KIF5B, KIF2C, PLK1 CENPE 50/4885ATM 1054/4885ALDH1A1 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.